Pioglitazone in Thyroid Cancers

Phase 2

Completed

• Conditions: Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
• Interventions: Drug: Pioglitazone

• Registration Number: NCT01655719
• Lead Sponsor: University of Michigan

Brief Summary

Through this trial the investigators hope to learn if a drug, Actos (pioglitazone), is useful in treating a certain kind of metastatic thyroid cancer. Actos is approved by the FDA to treat diabetes. It has not been approved by the FDA to treat cancer, so its use in this study is considered experimental.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-04
• Study First Submitted: 2012-07-25
• Study First Submitted QC: 2012-07-30
• Study First Posted: 2012-08-02
• Primary Completion: 2017-03-31
• Study Completion: 2017-03-31
• Results First Submitted: 2017-08-21
• Status Verified: 2017-09
• Results First Submitted QC: 2017-09-27
• Last Update Submitted: 2017-09-27
• Results First Posted: 2017-10-26
• Last Update Posted: 2017-10-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

1. Patients must have histologically confirmed thyroid carcinoma with the PAX8-PPARgamma translocation (translocation testing will be performed on archived tissue during the screening period).

   Refractory to radioactive iodine (RAI) as defined by: the tumor does not concentrate RAI; or the patient has had RAI within the last 16 months and has had progression despite that RAI; or the last RAI treatment was >16 months ago and the patient progressed after at least two RAI treatments; or the patient has received RAI treatments with a cumulative RAI dose of ≥22.2 GBq (600 mCi)

   Not a candidate for surgery or RAI therapy with curative intent.

   Lesions that would be treated by external beam radiation therapy (EBRT) based on standard of care can be so treated, but then cannot be used as target lesions.

2. Measurable disease by RECIST 1.1 criteria.

3. Documented disease progression by RECIST 1.1 in the past 14 months.

4. Availability of histological material (primary tumor or metastases) for review of the diagnosis and demonstration of PAX8-PPARgamma fusion gene.

5. Adequate TSH suppression (<0.5 mIU/L)

6. Prior chemotherapy or surgery must have been completed at least 28 days prior to registration, and all toxicities must have resolved.

7. Prior radioactive iodine must have been completed at least 6 months prior to registration, or there must be documented disease progression since such therapy if it was within 6 months. Sites that have received EBRT must have disease progression post-EBRT to be used as sites of measurable disease.

8. Life expectancy of greater than 6 months.

9. ECOG performance status 2 or less.

10. Patients must have normal organ function as defined below:

    AST(SGOT)/ALT(SGPT) less than 2.5 X institutional upper limit of normal (within 1 month of study Day 1)

11. Patients must be able to consume oral medications.

12. Women of childbearing potential must have a negative pregnancy test at baseline prior to receiving any study drug and must practice effective contraception while on study. (Pregnant or lactating patients are excluded).

13. All patients must sign an informed consent prior to enrollment.

Exclusion Criteria

1. Patients may not be receiving any other investigational agents.
2. Patients with known untreated brain metastases.
3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to pioglitazone.
4. Diagnosis of diabetes mellitus or current therapy with any drugs used to treat diabetes mellitus, including but not limited to insulin, sulfonylureas, metformin, rosiglitazone (Avandia), and pioglitazone (Actos) within 14 days of study Day 1
5. Therapy with rosiglitazone (Avandia) or pioglitazone (Actos) at any time since the diagnosis of thyroid cancer.
6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, congestive heart failure, unstable angina pectoris, or cardiac arrhythmias.
7. Pregnant women are excluded from this study because pioglitazone is a U.S. Food and Drug Administration Pregnancy Category C drug. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pioglitazone, breastfeeding should be discontinued if the mother is treated with pioglitazone.
8. No concurrent radiotherapy or chemotherapy may be given to the patient during the administration of the study drug.
9. Patients with uncontrolled malabsorption syndromes.
10. Patients with a history of congestive heart failure of any New York Heart Association class.
11. Any medical or psychiatric illness which, in the opinion of the principal investigator, would compromise the patient's ability to tolerate this treatment regimen.
12. Use of rifampin (strong CYP2C8 inducer) within 14 days of study Day 1.
13. Other current malignancy than the disease under study.
14. Grade 2 or worse edema within 14 days of study Day 1, per CTCAE v4.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Pioglitazone Treatment	Pioglitazone	If eligible, subjects can participate in 1 or both parts of this study as follows: Part 1: In the initial main portion of the study subjects will receive 24 -28 weeks of therapy with pioglitazone at the dosage approved for the control of diabetes. Response will be evaluated per RECIST. Safety measure are outlined in the protocol including weekly weigh ins, calls, labs, exams, etc. Part 2: A secondary protocol is then available to subjects who complete the main initial study with less than complete response per RECIST. They can undergo a radioiodine scan to see if the treatment with pioglitazone has sensitized their disease to radioiodine. If it has - they can pursue the radioiodine treatment.

Primary Outcome Measures

Name	Time	Method
Tumor Response (Change)	Baseline and 24 weeks	Response is measured by change in Tumor size (cm)

Secondary Outcome Measures

Name	Time	Method
Toxicity	24 weeks	Toxicities experienced by patients with PAX8-PPARgamma fusion gene-positive follicular-patterned thyroid carcinomas treated with pioglitazone are indicated by presence of Serious Adverse Events (that show relatedness).
Change in Serum Thyroglobulin	Baseline and 24 weeks	Determine if pioglitazone decreases serum thyroglobulin in patients with follicular-patterned thyroid carcinomas that contain the PAX8-PPARgamma fusion gene.

Trial Locations

Locations (4)

University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

University of Texas MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States

University of Colorado; 🇺🇸 Aurora, Colorado, United States